Sino Biopharmaceutical (HKG:1177) said the Phase III study of Benmelstobart combined with two other drugs for advanced squamous non-small cell lung cancer achieved positive results, allowing it to obtain China's consent to file a marketing application.

The combination of Benmelstobart Injection with chemotherapy and Anlotinib Hydrochloride Capsules was tested against Tislelizumab Injection with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC).

The Independent Data Monitoring Committee determined that the primary study endpoint of progression-free survival (PFS) has met the protocol's predefined superiority threshold, Sino Biopharm said.

The Chinese drugmaker said it will submit the marketing application "in the near future," according to a Friday filing with the Hong Kong bourse.